DK2257624T5 - Fremgangsmåder og sammensætninger - Google Patents
Fremgangsmåder og sammensætningerInfo
- Publication number
- DK2257624T5 DK2257624T5 DK09708496.6T DK09708496T DK2257624T5 DK 2257624 T5 DK2257624 T5 DK 2257624T5 DK 09708496 T DK09708496 T DK 09708496T DK 2257624 T5 DK2257624 T5 DK 2257624T5
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- methods
- compositions
- relates
- attached
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0802079.4A GB0802079D0 (en) | 2008-02-05 | 2008-02-05 | Method and compositions |
GB0818399A GB0818399D0 (en) | 2008-10-08 | 2008-10-08 | Methods and compositions |
PCT/GB2009/000301 WO2009098450A2 (en) | 2008-02-05 | 2009-02-04 | Methods and compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2257624T3 DK2257624T3 (da) | 2012-05-29 |
DK2257624T5 true DK2257624T5 (da) | 2012-09-10 |
Family
ID=40792924
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12151953.2T DK2474613T3 (da) | 2008-02-05 | 2009-02-04 | Fremgangsmåder og sammensætninger |
DK09708496.6T DK2257624T5 (da) | 2008-02-05 | 2009-02-04 | Fremgangsmåder og sammensætninger |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12151953.2T DK2474613T3 (da) | 2008-02-05 | 2009-02-04 | Fremgangsmåder og sammensætninger |
Country Status (11)
Country | Link |
---|---|
US (3) | US8680022B2 (da) |
EP (5) | EP2474613B2 (da) |
JP (2) | JP6074574B2 (da) |
AT (1) | ATE555200T1 (da) |
AU (1) | AU2009211253B2 (da) |
CA (1) | CA2714477C (da) |
DK (2) | DK2474613T3 (da) |
ES (2) | ES2383191T3 (da) |
PL (1) | PL2257624T3 (da) |
PT (1) | PT2257624E (da) |
WO (1) | WO2009098450A2 (da) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
GB0914110D0 (en) * | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
JP2013518807A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 多重特異性ペプチド |
JP2013518558A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 構造化されたペプチドプロセシング |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
JP6092104B2 (ja) * | 2010-08-13 | 2017-03-08 | ミティ・バイオシステムズ・ゲーエムベーハー | 修飾ペプチドディスプレイ |
GB201013980D0 (en) | 2010-08-20 | 2010-10-06 | Ecole Polytech | Bicyclic uPA inhibitors |
JP6157461B2 (ja) | 2011-06-30 | 2017-07-05 | ジェンザイム・コーポレーション | T細胞活性化の阻害剤 |
LT3299377T (lt) * | 2011-10-07 | 2021-03-25 | Bicyclerd Limited | Struktūrizuoto polipeptido specifiškumo moduliavimas |
GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
US9958437B2 (en) | 2012-02-03 | 2018-05-01 | The Governors Of The University Of Alberta | Method of quantifying peptide-derivative libraries using phage display |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
SG11201406769RA (en) | 2012-05-10 | 2014-11-27 | Massachusetts Inst Technology | Agents for influenza neutralization |
KR102165384B1 (ko) | 2012-08-07 | 2020-10-16 | 메사추세츠 인스티튜트 오브 테크놀로지 | 항-뎅기 바이러스 항체 및 이들의 용도 |
JP6306596B2 (ja) | 2012-10-04 | 2018-04-04 | リサーチ ディベロップメント ファウンデーション | セリンプロテアーゼ分子および療法 |
EA201591049A1 (ru) * | 2012-11-30 | 2015-09-30 | Новартис Аг | Способы получения конъюгатов дисульфидсодержащих белков |
GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
WO2014190257A2 (en) * | 2013-05-23 | 2014-11-27 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
US10526375B2 (en) | 2013-06-05 | 2020-01-07 | Massachusetts Institute Of Technology | Human Adaptation of H7 HA |
SG10201810067YA (en) | 2013-08-14 | 2018-12-28 | Univ Rice William M | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
ES2715379T3 (es) * | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
WO2015123362A1 (en) | 2014-02-11 | 2015-08-20 | Massachusetts Institute Of Technology | Novel full spectrum anti-dengue antibody |
EP3137482A1 (en) | 2014-05-02 | 2017-03-08 | MorphoSys AG | Peptide libraries |
GB201413086D0 (en) | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
EP4350056A2 (en) | 2014-10-22 | 2024-04-10 | The Governors Of The University Of Alberta | Genetic encoding of chemical post-translational modification for phage-displayed libraries |
CA2965754C (en) | 2014-10-29 | 2024-01-02 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
KR101693665B1 (ko) * | 2014-11-13 | 2017-01-06 | 목포해양대학교 산학협력단 | 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법 |
MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
JP6609099B2 (ja) * | 2014-12-10 | 2019-11-20 | キヤノン株式会社 | 放射線検出装置、及び放射線検出シート |
CN107109403A (zh) | 2014-12-22 | 2017-08-29 | 莫佛塞斯公司 | 在噬菌体颗粒上展示环肽的新方法 |
EP3286314B1 (en) * | 2015-04-23 | 2019-06-26 | H. Hoffnabb-La Roche Ag | Cow antibody scaffold polypeptide method and composition |
JP2015214568A (ja) * | 2015-07-13 | 2015-12-03 | バイスクル・セラピューティクス・リミテッド | 多重特異性ペプチド |
US11193117B2 (en) | 2016-02-16 | 2021-12-07 | Research Development Foundation | Cell-targeted cytotoxic constructs |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
JP7093300B2 (ja) | 2016-06-07 | 2022-06-29 | 株式会社カネカ | リボソームディスプレイ複合体およびその製造方法 |
TWI781963B (zh) | 2016-11-09 | 2022-11-01 | 俄亥俄州立創新基金會 | 含二硫化物細胞穿透肽及其製造與使用方法 |
US10913773B2 (en) | 2016-11-22 | 2021-02-09 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha |
US11352394B2 (en) | 2016-11-22 | 2022-06-07 | Ohio State Innovation Foundation | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof |
US10441663B2 (en) | 2016-11-27 | 2019-10-15 | Bicyclerd Limited | Methods for treating cancer |
AU2017371472A1 (en) | 2016-12-06 | 2019-06-27 | Stichting Voor De Technische Wetenschappen | Multicyclic peptides and methods for their preparation |
CN110603261A (zh) * | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
CN110506049A (zh) * | 2016-12-23 | 2019-11-26 | 拜斯科技术开发有限公司 | 用于结合mt1-mmp的肽配体 |
US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
EP3635115A1 (en) | 2017-06-09 | 2020-04-15 | Vib Vzw | Glutamine dehydrogenase inhibitors for use in muscle regeneration |
CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
EP3655013B1 (en) | 2017-07-17 | 2022-04-13 | Vib Vzw | Targeting synaptogyrin-3 in tauopathy treatment |
CN111183147A (zh) * | 2017-08-04 | 2020-05-19 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
EP3668550A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
WO2019081714A1 (en) | 2017-10-26 | 2019-05-02 | Vib Vzw | POSITIVE MACROPHAGES TO PODOPLANIN |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
EP3755725A1 (en) | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
CN112236442A (zh) | 2018-04-04 | 2021-01-15 | 拜斯科技术开发有限公司 | 异源串联双环肽复合物 |
US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
GB201808835D0 (en) * | 2018-05-30 | 2018-07-11 | Bicyclerd Ltd | Ligands and methods of selecting binding targets for such |
GB201810329D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
GB201810327D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
GB201810320D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
GB201810316D0 (en) * | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
GB201810325D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
WO2020019072A1 (en) * | 2018-07-23 | 2020-01-30 | The Governors Of The University Of Alberta | Genetically-encoded bicyclic peptide libraries |
US11655468B2 (en) | 2018-07-25 | 2023-05-23 | The Trustees Of Boston College | Methods and compositions of chemically modified phage libraries |
WO2020023620A1 (en) * | 2018-07-25 | 2020-01-30 | Trustees Of Boston College | Methods and compositions of chemically modified phage libraries |
WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
GB201819659D0 (en) | 2018-12-03 | 2019-01-16 | Vib Vzw | Cancer regression by inducing a regeneration-like reponse |
GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
GB201820316D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for IL-17 |
GB201820320D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
US20220024982A1 (en) | 2018-12-13 | 2022-01-27 | Bicycletx Limited | Bicyclic peptide ligands specific for mt1-mmp |
EP3897850A1 (en) | 2018-12-21 | 2021-10-27 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
WO2020128526A1 (en) | 2018-12-21 | 2020-06-25 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
GB201900530D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for CD38 |
GB201900525D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for caix |
GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
GB201900526D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
GB201900527D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for integrin avb3 |
GB201900528D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for integrin AVB3 |
WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
EP3935069A1 (en) | 2019-03-04 | 2022-01-12 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
CA3137095A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
US20220220197A1 (en) | 2019-05-28 | 2022-07-14 | Vib Vzw | Cancer Treatment by Targeting Plexins in the Immune Compartment |
US20220228116A1 (en) | 2019-05-28 | 2022-07-21 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
AU2020325658A1 (en) | 2019-08-07 | 2022-01-06 | Gyros Protein Technologies AB | A method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules |
US20220275053A1 (en) | 2019-08-13 | 2022-09-01 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
GB201912320D0 (en) | 2019-08-28 | 2019-10-09 | Bicycletx Ltd | PBP Binding Bicyclic Peptide Ligands |
GB201914233D0 (en) | 2019-10-02 | 2019-11-13 | Bicyclerd Ltd | Phage cyclisation assay |
JP2022551607A (ja) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
GB201914872D0 (en) | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
CN114760988A (zh) | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
CN114787177A (zh) | 2019-12-16 | 2022-07-22 | 拜斯科技术开发有限公司 | Il-17特异性的双环肽配体 |
GB201918559D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
GB201918557D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
GB201918558D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
CN110907422B (zh) * | 2019-12-16 | 2021-07-06 | 吉林大学 | 基于Ti3C2的凝血酶适体传感器及其制备方法 |
GB202002705D0 (en) | 2020-02-26 | 2020-04-08 | Bicycletx Ltd | Anti-infective bicyclic peptide conjugates |
GB202002706D0 (en) | 2020-02-26 | 2020-04-08 | Bicycletx Ltd | Pbp3 binding bicyclic peptide ligands |
JP2023520714A (ja) | 2020-04-06 | 2023-05-18 | バイスクルテクス・リミテッド | Tslpに特異的な二環式ペプチドリガンド |
WO2021220011A1 (en) | 2020-05-01 | 2021-11-04 | Bicycletx Limited | Anti-infective bicyclic peptide conjugates |
EP4149954A1 (en) | 2020-05-15 | 2023-03-22 | BicycleTX Limited | Anti-infective bicyclic peptide ligands |
KR20230065231A (ko) | 2020-06-12 | 2023-05-11 | 바이사이클티엑스 리미티드 | 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료 |
BR112023001428A2 (pt) | 2020-08-03 | 2023-02-23 | Bicycletx Ltd | Ligantes à base de peptídios |
CN111893577B (zh) * | 2020-08-06 | 2022-03-22 | 厦门大学 | 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法 |
KR20230074721A (ko) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도 |
CA3196737A1 (en) | 2020-09-24 | 2022-03-31 | Massimiliano Mazzone | Combination of p2y6 inhibitors and immune checkpoint inhibitors |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
GB202016331D0 (en) | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
CN116802190A (zh) | 2020-11-13 | 2023-09-22 | 拜斯科技术开发有限公司 | 特异于转铁蛋白受体1(TfR1)的双环肽配体 |
CA3206525A1 (en) | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Anti-infective bicyclic peptide ligands |
AU2022206577A1 (en) | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
WO2022148968A1 (en) | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Anti-infective bicyclic peptide ligands |
US20240083944A1 (en) | 2021-01-08 | 2024-03-14 | Bicycle TX Limited | Anti-infective bicyclic peptide ligands |
WO2022148970A1 (en) | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Anti-infective bicyclic peptide ligands |
CN117157305A (zh) | 2021-01-08 | 2023-12-01 | 拜斯科技术开发有限公司 | 抗感染的双环肽配体 |
JP2024502351A (ja) | 2021-01-08 | 2024-01-18 | バイスクルテクス・リミテッド | Nk細胞に特異的な二環式ペプチドリガンド |
JP2024502189A (ja) | 2021-01-11 | 2024-01-17 | バイシクルティーエクス・リミテッド | 癌を処置する方法 |
EP4281034A1 (en) | 2021-01-24 | 2023-11-29 | Forrest, Michael, David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
EP4294407A1 (en) | 2021-02-17 | 2023-12-27 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
WO2022195287A1 (en) | 2021-03-19 | 2022-09-22 | Bicycletx Limited | Bicyclic peptide ligands specific for trem2 |
WO2022199804A1 (en) | 2021-03-24 | 2022-09-29 | Vib Vzw | Nek6 inhibition to treat als and ftd |
JP2024515306A (ja) | 2021-04-20 | 2024-04-08 | バイスクルテクス・リミテッド | P-セレクチンに特異的な二環式ペプチドリガンド |
CA3227511A1 (en) | 2021-08-06 | 2023-02-09 | Lætitia LINARES | Methods for the treatment of cancer |
CA3229976A1 (en) | 2021-09-03 | 2023-03-09 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
GB202114279D0 (en) | 2021-10-06 | 2021-11-17 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
GB202114282D0 (en) | 2021-10-06 | 2021-11-17 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
GB202116266D0 (en) | 2021-11-11 | 2021-12-29 | Bicycletx Ltd | Novel use |
GB202116263D0 (en) | 2021-11-11 | 2021-12-29 | Bicycletx Ltd | Anti-infective bicyclic peptide ligands |
CN114166924A (zh) * | 2021-12-03 | 2022-03-11 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
WO2023139292A1 (en) | 2022-01-24 | 2023-07-27 | Cambridge Enterprise Limited | Tau therapy |
GB202206431D0 (en) | 2022-05-03 | 2022-06-15 | Bicycletx Ltd | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) |
WO2024009108A1 (en) | 2022-07-07 | 2024-01-11 | Bicycletx Limited | Anti-infective bicyclic peptide ligands |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9313509D0 (en) * | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
US6063819A (en) * | 1997-02-21 | 2000-05-16 | Cypros Pharmaceutical Corp. | Neuroprotective poly-guanidino compounds which block presynaptic N and P/Q calcium channels |
IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
AU7839700A (en) * | 1999-09-29 | 2001-04-30 | Ronald W. Barrett | Compounds displayed on replicable genetic packages and methods of using same |
WO2002077182A2 (en) | 2001-03-21 | 2002-10-03 | Xenoport, Inc. | Compounds displayed on icosahedral phage and methods of using same |
EP1504111A4 (en) | 2002-04-19 | 2005-11-23 | California Inst Of Techn | PEPTIDES NUCLEIC ACID PEPTIDE DISPLAY LIBRARS CONTAINING UNNATURELY AMINO-ACID-RESISTANT AND METHOD FOR THE PRODUCTION THEREOF |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
DK1844337T3 (da) * | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
WO2006095345A2 (en) | 2005-03-08 | 2006-09-14 | Ramot At Tel-Aviv University Ltd. | Targeted drug-carrying bacteriophages |
WO2008013454A2 (en) * | 2006-07-26 | 2008-01-31 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
AU2007336132A1 (en) * | 2006-12-21 | 2008-06-26 | Cytos Biotechnology Ag | Circular CCR5 peptide conjugates and uses thereof |
-
2009
- 2009-02-04 EP EP12151953.2A patent/EP2474613B2/en active Active
- 2009-02-04 JP JP2010545546A patent/JP6074574B2/ja active Active
- 2009-02-04 AT AT09708496T patent/ATE555200T1/de active
- 2009-02-04 ES ES09708496T patent/ES2383191T3/es active Active
- 2009-02-04 EP EP09708496A patent/EP2257624B9/en active Active
- 2009-02-04 EP EP13167203.2A patent/EP2653544A1/en not_active Ceased
- 2009-02-04 US US12/866,214 patent/US8680022B2/en active Active
- 2009-02-04 DK DK12151953.2T patent/DK2474613T3/da active
- 2009-02-04 DK DK09708496.6T patent/DK2257624T5/da active
- 2009-02-04 ES ES12151953.2T patent/ES2509959T3/es active Active
- 2009-02-04 PL PL09708496T patent/PL2257624T3/pl unknown
- 2009-02-04 PT PT09708496T patent/PT2257624E/pt unknown
- 2009-02-04 AU AU2009211253A patent/AU2009211253B2/en active Active
- 2009-02-04 CA CA2714477A patent/CA2714477C/en active Active
- 2009-02-04 WO PCT/GB2009/000301 patent/WO2009098450A2/en active Application Filing
- 2009-02-04 EP EP13167204.0A patent/EP2653545A1/en not_active Withdrawn
- 2009-02-04 EP EP13167202.4A patent/EP2653543A1/en not_active Withdrawn
-
2013
- 2013-08-22 US US13/973,297 patent/US9657288B2/en active Active
-
2014
- 2014-07-23 US US14/339,327 patent/US9670484B2/en active Active
-
2015
- 2015-01-23 JP JP2015011208A patent/JP6075658B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
AU2009211253A1 (en) | 2009-08-13 |
ES2509959T3 (es) | 2014-10-20 |
EP2474613B2 (en) | 2022-02-16 |
ES2383191T9 (es) | 2012-10-16 |
DK2474613T3 (da) | 2014-10-06 |
EP2474613B1 (en) | 2014-07-16 |
JP2011514803A (ja) | 2011-05-12 |
EP2653545A1 (en) | 2013-10-23 |
PT2257624E (pt) | 2012-05-29 |
EP2257624B1 (en) | 2012-04-25 |
EP2257624B9 (en) | 2012-08-01 |
EP2653543A1 (en) | 2013-10-23 |
US9657288B2 (en) | 2017-05-23 |
EP2257624A2 (en) | 2010-12-08 |
ATE555200T1 (de) | 2012-05-15 |
WO2009098450A3 (en) | 2009-10-29 |
EP2474613A1 (en) | 2012-07-11 |
DK2257624T3 (da) | 2012-05-29 |
EP2653544A1 (en) | 2013-10-23 |
PL2257624T3 (pl) | 2012-09-28 |
CA2714477A1 (en) | 2009-08-13 |
JP6074574B2 (ja) | 2017-02-08 |
US20140187757A1 (en) | 2014-07-03 |
JP2015109856A (ja) | 2015-06-18 |
US9670484B2 (en) | 2017-06-06 |
JP6075658B2 (ja) | 2017-02-08 |
ES2383191T3 (es) | 2012-06-19 |
US8680022B2 (en) | 2014-03-25 |
CA2714477C (en) | 2018-10-16 |
WO2009098450A2 (en) | 2009-08-13 |
AU2009211253B2 (en) | 2014-11-06 |
US20100317547A1 (en) | 2010-12-16 |
US20150166988A1 (en) | 2015-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2474613T3 (da) | Fremgangsmåder og sammensætninger | |
EA201170168A1 (ru) | Комплекс (минерал-аминокислота)-полисахарид | |
MX2009007695A (es) | Compuestos complejos de carbohidrato de hierro. | |
NZ603495A (en) | Algorithm for designing irreversible inhibitors | |
CY1110010T1 (el) | Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4) | |
SG162687A1 (en) | Caustic stable chromatography ligands | |
MX2008012627A (es) | Metodos para producir materiales de estructura metalica-organica conteniendo metales del subgrupo iv. | |
IL187838A0 (en) | Production of il-18 binding protein | |
GB0521508D0 (en) | Organic compounds | |
MX2010002463A (es) | Plantas con rasgos relacionados con un rendimiento aumentado y un metodo para producirlas. | |
GB2453808A8 (en) | Novel compounds from antrodia camphorata | |
CY1113716T1 (el) | Νεα μεθοδος συνθεσης της αγομελατινης | |
WO2012059873A3 (en) | Anti-diabetic compounds | |
MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
WO2009097626A3 (en) | Paired-end reads in sequencing by synthesis | |
CY1112829T1 (el) | Νεα μεθοδος συνθεσης για την αγομελατινη | |
IL265947A (en) | Preparation of stansoporfin with a high degree of purification on a large scale | |
DE602006020881D1 (de) | Enen eigenschaften | |
EA201101152A1 (ru) | Лиофилизированный дабигатран | |
HK1120817A1 (en) | Process for production of polymerized coordination compound of platinum complex | |
TW200631939A (en) | Process for cross coupling indoles | |
DK1926732T3 (da) | Fremgangsmåde til fremstillingen af carbapenemforbindelser | |
ATE529413T1 (de) | Verfahren zur synthese von aryloxydiaminopyrimidinen | |
EA200702428A1 (ru) | Способы получения 4-бифенилилазетидин-2-онов | |
WO2007014076A3 (en) | Methods of producing modified assembly lines and related compositions |